All In Biotech

Investigational drug · Phase 2

KAND567

Also called: Fractalkine

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jun 8, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

3

Any phase or sponsor naming "KAND567"

First trial start

2023

Apr 26, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "KAND567", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Epithelial Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Cancer

Approved drugs for the same conditions: Ovarian cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "KAND567" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2,155 on PubMed

Also in development for Epithelial Ovarian Cancer

  • BL-M07D1Phase 317 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors

  • AZD5335Torvutatug samrotecan, Torvu-samPhase 34 trials

    AstraZeneca · Epithelial Ovarian Cancer, Ovarian Cancer, Lung Adenocarcinoma

  • IMNN-001IL-12 Plasmid with PEG-PEI-Cholesterol Lipopolymer, GEN-1Phase 33 trials

    Imunon · Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer

  • RC88The RC88Phase 23 trials

    RemeGen Co., Ltd. · Solid Tumor, Advanced Solid Tumours, Primary Peritoneal Cancer

  • AVZO-021Phase 22 trials

    Avenzo Therapeutics, Inc. · HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, Advanced Solid Tumor

  • Beijing Biotech · Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma

  • CBX-12Phase 21 trial

    Cybrexa Therapeutics · Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma

  • ETX-19477Phase 21 trial

    858 Therapeutics, Inc. · Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.